Search - tctmd.com

Displaying 1 - 15 of 15

Sort: Relevancy | Date

Presentation ESC 2025

AQUATIC: Assessment of Quitting versus Using Aspirin Therapy In patients with stabilized Coronary artery disease after stenting who require long-term oral anticoagulation

Presenter: Martine Gilard

August 30, 2025

Presentation ESC 2023

Post procedural anticoagulation after primary percutaneous coronary intervention for ST segment elevation myocardial infarction: a multicentre, randomised, double blind trial

Presenter: Shaoping Nie

August 28, 2023

Presentation

Antithrombotic Therapy and CV Outcomes After TAVR in A-fib Patients

August 20, 2019

Presentation EuroPCR 2017

Efficacy and Safety of LAA Closure with WATCHMAN in Patients with or without Contraindication to Oral Anticoagulation: 1-year FU of the EWOLUTION trial

Presenter: Lucas Boersma, Martin W. Bergmann

May 18, 2017

Presentation

Safety and Use of Anticoagulation After Aortic Valve Replacement With Bioprostheses

Presenter: Haris Riaz

May 11, 2016

Presentation

Impact of Anticoagulation Regimen Prior toRevascularization in Patients With NSTE-ACS

Presenter: Tobias Geisler

September 18, 2015

Presentation

6 Months vs Extended Oral Anticoagulation After a First Episode of Pulmonary Embolism

Presenter: Francis Couturaud

July 10, 2015

Presentation

Duration of Triple Therapy in Patients Requiring Oral Anticoagulation After DES Implantation

Presenter: K.A. Fiedler

April 22, 2015

Presentation

ACC 2015 Late Breaking Trials: PCI Access and Anticoagulation Trials

Presenter: Gregg W. Stone

April 14, 2015

Presentation Cardiovascular Interventions 2014

How to Manage Post PCI Antiplatelet Therapy in the Patient on Oral Anticoagulation

Presenter: David P. Faxon

October 23, 2014

Presentation

Use and Associated Risks of Concomitant Aspirin with Oral Anticoagulation in A-fib Patients

Presenter: B. A. Steinberg

July 24, 2013

Presentation

Oral Anticoagulation (OAC) and Antiplatelets inA-fib Patients After MI and PCI

Presenter: M. Lamberts

June 12, 2013

Presentation PCI Outcomes 2013

DAPT + Oral Anticoagulation: Indications and Risk Amelioration

Presenter: C. Michael Gibson

March 07, 2013

Presentation TCT 2013

Can the Rate of Acute Stent Thrombosis with Bivalirudin Anticoagulation During Primary PCI in STEMI be Reduced with Modified Pharmacologic Regimens?

Presenter: Andreas Baumbach, Harold Dauerman, Bernardo Cortese, Martial Hamon, Jayne Prats, Efthymios Deliargyris, Roxana Mehran, Gregg Stone

January 31, 2013

Presentation TCT Mediterranean 2012

Anticoagulation in ACS: Role of Bivalirudin

Presenter: Gregg W. Stone

May 04, 2012

Advertisement

AQUATIC: Assessment of Quitting versus Using Aspirin Therapy In patients with stabilized Coronary artery disease after stenting who require long-term oral anticoagulation

Post procedural anticoagulation after primary percutaneous coronary intervention for ST segment elevation myocardial infarction: a multicentre, randomised, double blind trial

Antithrombotic Therapy and CV Outcomes After TAVR in A-fib Patients

Efficacy and Safety of LAA Closure with WATCHMAN in Patients with or without Contraindication to Oral Anticoagulation: 1-year FU of the EWOLUTION trial

Safety and Use of Anticoagulation After Aortic Valve Replacement With Bioprostheses

Impact of Anticoagulation Regimen Prior toRevascularization in Patients With NSTE-ACS

6 Months vs Extended Oral Anticoagulation After a First Episode of Pulmonary Embolism

Duration of Triple Therapy in Patients Requiring Oral Anticoagulation After DES Implantation

ACC 2015 Late Breaking Trials: PCI Access and Anticoagulation Trials

How to Manage Post PCI Antiplatelet Therapy in the Patient on Oral Anticoagulation

Use and Associated Risks of Concomitant Aspirin with Oral Anticoagulation in A-fib Patients

Oral Anticoagulation (OAC) and Antiplatelets inA-fib Patients After MI and PCI

DAPT + Oral Anticoagulation: Indications and Risk Amelioration

Can the Rate of Acute Stent Thrombosis with Bivalirudin Anticoagulation During Primary PCI in STEMI be Reduced with Modified Pharmacologic Regimens?

Anticoagulation in ACS: Role of Bivalirudin

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content